| Identification | Back Directory | [Name]
3-[(5Z)-5-[[5-(4-nitrophenyl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoic acid | [CAS]
851304-36-4 | [Synonyms]
KYA1797
3-[(5Z)-5-[[5-(4-nitrophenyl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoic acid | [Molecular Formula]
C17H12N2O6S2 | [MOL File]
851304-36-4.mol | [Molecular Weight]
404.42 |
| Hazard Information | Back Directory | [Description]
KYA1797 is a novel inhibitor of the Wnt/?-catenin pathway, binding directly to the regulators of G-protein signaling domain of axin, initiating ?-catenin and Ras degradation through enhancement of the ?-catenin destruction complex activating GSK3?, effectively suppressing the growth of CRCs harboring APC and KRAS mutations. |
|
| Company Name: |
PHARMEKS Ltd.
|
| Tel: |
+7 (495) 702-9648 |
| Website: |
www.pharmeks.com |
|